Evaluating the Effectiveness of 68Ga-grazytracer PET/CT in Inflammatory Bowel Disease
Not applicable · Testing 68Ga-grazytracer PET/CT Scan · 1 site · Xijing Hospital
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
This study is testing 68Ga-grazytracer PET/CT Scan (a diagnostic test) as a way to diagnose or measure disease. Condition(s) listed: Inflammatory Bowel Diseases (IBD).
It is open-label: participants know what they are receiving.
This study does not use drug-development phases (it may test a device, diet, procedure, app, or care approach).
Who can join
- Ages 18 to 80
- Any sex
Some of the main requirements, copied from the record:
- Age between 18-80 years old; Clinical diagnosis of inflammatory bowel disease (active stage); Not having received treatment within 4 weeks prior to undergoing PET/CT examination; Received endoscopy within 7 days before and after PET/CT…
There are also 1 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 69 participants are expected to take part.
- Start date: 2025-06-15 (planned).
- Main results expected around 2027-12-31 (estimate from the record).
- 1 study site listed in China.
Main thing being measured
- Maximum Standardized uptake value (1 day from injection of the tracer)
In the researchers’ words
This is a single-centre, prospective, observational cohort study in which 69 patients with inflammatory bowel disease (IBD) were recruited to undergo 68Ga-grazytracer PET/CT imaging in patients with IBD to investigate the feasibility of early sensitive detection or prediction of the response to medication in patients with inflammatory bowel disease on 68Ga-grazytracer PET/CT and early prediction of the The…
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Not applicable |
| Study type | Interventional |
| Conditions | Inflammatory Bowel Diseases (IBD) |
| Lead sponsor | Xijing Hospital |
| Enrollment | 69 (estimated) |
| Start date | 2025-06-15 |
| Primary completion (est.) | 2027-12-31 |
| First posted | 2025-06-15 |
| Last updated | 2025-06-15 |
| Official title | 68Ga-grazytracer PET/CT Study in Inflammatory Bowel Disease |
| ClinicalTrials.gov ID | NCT07022080 |
Interventions
- 68Ga-grazytracer PET/CT Scan (Diagnostic Test)
The imaging agent 68Ga-grazytracer used in this project is synthesised in accordance with the standards for the production of radiopharmaceuticals with reference to the Chinese Pharmacopoeia (18F-FDG quality standard). pH value is between 5.0-8.0; radiochemical purity is not less than 95%, and the content of bacterial endotoxin per mL of solution is less than 15EU; the concentration of radioactivi…
Full eligibility criteria (from the record)
Inclusion Criteria: * Age between 18-80 years old; Clinical diagnosis of inflammatory bowel disease (active stage); Not having received treatment within 4 weeks prior to undergoing PET/CT examination; Received endoscopy within 7 days before and after PET/CT examination; Signing an informed consent form for PET/CT examination and volunteering to participate in this study. Exclusion Criteria: * No signed informed consent or unspecified diagnosis; Female subjects are pregnant or breastfeeding and male subjects are preparing for pregnancy; Those who are unfit to perform (concomitant severe and/or uncontrollable and/or unstable disease, developer allergy) or who are unable to complete imaging such as PET for specific reasons (needle-sickness, blood-sickness, claustrophobia); Colitis other than inflammatory bowel disease (infectious or ischaemic colitis); Patients who have undergone colon resection.
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical University, Xi'an, China, Xi'an, Shaanxi Province | Xi'an, Shaanxi | China |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.